Affordable Access

deepdyve-link
Publisher Website

Non-alcoholic fatty liver disease: A poorly known pandemic.

Authors
  • Augustin, Salvador1
  • Graupera, Isabel2
  • Caballeria, Juan3
  • 1 Servei de Medicina Interna, Hospital Vall d'Hebron, Barcelona, España.
  • 2 Unidad de Hepatología, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España.
  • 3 Unidad de Hepatología, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España. Electronic address: [email protected]
Type
Published Article
Journal
Medicina Clínica
Publisher
Elsevier
Publication Date
Jul 24, 2017
Identifiers
DOI: 10.1016/j.medcli.2017.06.026
PMID: 28751080
Source
Medline
Keywords
License
Unknown

Abstract

Non-alcoholic fatty liver disease (NAFLD) consists of an excessive depositing of fat in the liver, which can end up by causing inflammation, fibrosis and also cirrhosis with the corresponding complications including liver cancer. NAFLD has become the most common liver disease worldwide. The incidence has increased in parallel with the obesity, diabetes and metabolic syndrome epidemic, thus resulting in becoming one of the main indications for liver transplant. The diagnosis has principally been through histology but with the development of non-invasive methods, these have helped in simplifying the management of these patients in clinical practice. The only therapeutic strategies currently available are focused on weight loss (lifestyle changes or bariatric surgery). There is still no approved pharmacological option for the treatment of NAFLD, however there are a number of molecular studies in advanced stages of development.

Report this publication

Statistics

Seen <100 times